Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial. by de Barros, Barbara et al.
1de Barros B, et al. BMJ Open 2020;10:e037700. doi:10.1136/bmjopen-2020-037700
Open access 
Methotrexate and prednisolone study in 
erythema nodosum leprosum (MaPs in 
ENL) protocol: a double- blind 
randomised clinical trial
Barbara de Barros   ,1 Saba M Lambert   ,1,2 Mahesh Shah,3 Vivek V Pai,4 
Joydeepa Darlong,5 Benjamin Jewel Rozario,6 Medhi Denisa Alinda,7 
Anna M Sales,8 Shimelis Doni,2 Deanna A Hagge,3 Dilip Shrestha,3 
M. Yulianto Listiawan,7 Abeba M Yitaye,2 Jose A C Nery,8 Kapil D Neupane,3 
Vivianne L A Dias,8 C. Ruth Butlin,6 Peter G Nicholls,1 Diana Lockwood,1 
Stephen L Walker   1
To cite: de Barros B, 
Lambert SM, Shah M, 
et al.  Methotrexate and 
prednisolone study in 
erythema nodosum leprosum 
(MaPs in ENL) protocol: a 
double- blind randomised 
clinical trial. BMJ Open 
2020;10:e037700. doi:10.1136/
bmjopen-2020-037700
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2020- 037700).
Received 13 February 2020
Revised 07 October 2020
Accepted 23 October 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Barbara de Barros;  
 barbara. de- barros@ lshtm. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Erythema nodosum leprosum (ENL) is an 
immunological complication of leprosy. ENL results in 
morbidity and disability and if it is not treated can lead to 
death. The current treatment consists of thalidomide or 
high doses of oral corticosteroids for prolonged periods. 
Thalidomide is not available in many leprosy endemic 
countries. The use of corticosteroids is associated with 
morbidity and mortality. Identifying treatment regimens 
that reduce the use of corticosteroids in ENL is essential. 
Methotrexate (MTX) is used to treat many inflammatory 
diseases and has been used successfully to treat 
patients with ENL not controlled by other drugs, including 
prednisolone and thalidomide. We present the protocol of 
the ‘MTX and prednisolone study in ENL’ (MaPs in ENL) 
a randomised controlled trial (RCT) designed to test the 
efficacy of MTX in the management of ENL.
Methods and analysis MaPs in ENL is an international 
multicentre RCT, which will be conducted in leprosy 
referral centres in Bangladesh, Brazil, Ethiopia, India, 
Indonesia and Nepal. Patients diagnosed with ENL who 
consent to participate will be randomly allocated to 
receive 48 weeks of weekly oral MTX plus 20 weeks of 
prednisolone or 48 weeks of placebo plus 20 weeks of 
prednisolone. Participants will be stratified by type of 
ENL into those with acute ENL and those with chronic 
and recurrent ENL. The primary objective is to determine 
whether MTX reduces the requirement for additional 
prednisolone. Patients’ reported outcome measures will 
be used to assess the efficacy of MTX. Participants will be 
closely monitored for adverse events.
Ethics and dissemination Results will be submitted for 
publication in peer- reviewed journals. Ethical approval 
was obtained from the Observational/Interventions 
Research Ethics Committee of the London School of 
Hygiene & Tropical Medicine (15762); The Leprosy Mission 
International Bangladesh Institutional Research Board 
(in process); AHRI- ALERT Ethical Review Committee, 
Ethiopia; Ethics Committee of the Managing Committee 
of the Bombay Leprosy Project; and The Leprosy Mission 
Trust India Ethics Committee; the Nepal Health and 
Research Council and Health Research Ethics Committee 
Dr. Soetomo, Indonesia. This study is registered at www. 
clinicaltrials. gov. This is the first RCT of MTX for ENL and 




Erythema nodosum leprosum (ENL) is an 
immunological complication of borderline 
lepromatous (BL) leprosy and lepromatous 
leprosy (LL).1 ENL affects up to 50% of indi-
viduals with LL and approximately 5%–10% 
of patients with BL.1 2 It is estimated that over 
50 000 new patients with leprosy diagnosed 
each year are at risk developing of ENL,3 
which may occur before, during or after 
successful completion of multidrug therapy 
(MDT). The inflammatory state of ENL 
causes significant morbidity and may be asso-
ciated with death.3 4 Having a family member 
with ENL may produce severe economic 
hardship.5
Strengths and limitations of this study
 ► This is the first randomised controlled trial to eval-
uate efficacy of methotrexate (MTX) in the manage-
ment of erythema nodosum leprosum (ENL).
 ► We will use the Erythema Nodosum Leprosum 
International STudy ENL Severity Scale to evaluate 
the severity of ENL to ensure consistency of patient 
recruitment between the study centres.
 ► Participants will be stratified according to the type of 
ENL acute or chronic and recurrent.
 ► Data will be collected on adverse events.
 ► MTX can cause severe nausea, which may lead to 
loss of allocation concealment.
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ENL is a multisystem inflammatory disorder charac-
terised by extensive crops of painful skin lesions, fever, 
arthralgia, arthritis, osteitis, dactylitis, lymphadenitis, 
iritis, orchitis and neuritis. When severe, lesions may 
ulcerate. ENL is often chronic requiring treatment for 
several years.1
The histology of ENL skin lesions classically shows an 
intense perivascular infiltrate of neutrophils throughout 
the dermis and subcutis.6 There is evidence of neutro-
phils and immune complexes playing a role in the inflam-
mation associated with ENL, yet it is uncertain whether 
they initiate the process.7 There is also evidence of T 
lymphocyte and macrophage activation and expression 
of mRNA for Tumor Necrosis Factor-α (TNFα) and IL-12 
in the skin.8 Several studies have shown increased levels of 
TNFα, IL-6, IL-12 and IL-17, in skin and blood.7 9 10
Patients with ENL are treated with corticosteroids and/
or thalidomide, which are used for prolonged periods 
of months or even years.4 Thalidomide is effective for 
many individuals with ENL but is not readily available 
in many countries because of its teratogenic effects.11 12 
Thalidomide is also associated with adverse effects such as 
somnolence, nausea, neurotoxicity, dizziness and throm-
boembolism, which may limit its use.13 Many patients 
require prolonged, high doses of corticosteroids to 
control their inflammation that are associated with 
morbidity and in some settings death.3
The identification of other agents for controlling ENL 
is a priority.14 Since the introduction of MDT, there 
have been eight randomised controlled trials (RCTs) of 
potential treatments for ENL, involving just 369 (median 
22 (range 10–100)) individuals and all had significant 
methodological limitations including lack of standardisa-
tion, allocation concealment and non- validated outcome 
measures.15–22
Rationale for using methotrexate
Methotrexate (MTX) is an immunosuppressant agent 
used in the treatment of malignant and inflammatory 
diseases.23 24 MTX was first introduced in 1948 to treat 
acute leukaemia and in 1951, Gubner published his find-
ings on the rapid improvement of psoriasis in patients 
being treated with aminopterin, an unstable precursor 
of MTX.25 Low doses of oral MTX are widely used in 
paediatric and adult care to manage TNF-α-driven auto-
immune and inflammatory diseases including psoriasis, 
inflammatory spondylo- arthritides, vasculitis and inflam-
matory bowel disease, in doses between 7.5 mg and 25 mg 
once a week.26 MTX is included in the WHO model list of 
essential medicines.27
The mechanisms by which low- dose oral MTX exerts its 
clinical effects are not fully understood. However, there 
is evidence of action on proinflammatory cytokines such 
as TNF-α, IL-1, IL-6 and immune- regulation pathways.28
Dermatologists and leprologists are familiar with using 
MTX, which is widely available and affordable in compar-
ison to other agents used to manage ENL. There are 
reports, including a case series of MTX having a beneficial 
effect in the management of ENL,29–31 however, there are 
no controlled trials of MTX in ENL.
MTX may take up to 12 weeks for a therapeutic effect 
to be noticeable in psoriasis.24 We hypothesise that MTX 
used in conjunction with prednisolone will improve the 
clinical outcomes for patients with ENL.
METHODS AND ANALYSIS
Definitions
ENL is defined as occurring when an individual with BL 
or LL leprosy develops 10 or more tender papular and/
or nodular skin lesions.
Three clinical patterns of ENL are described: single 
acute episodes, recurrent episodes and chronic.1 3 20
Acute ENL is defined as occurring if a patient has 
either a first episode of ENL of less than 24 weeks dura-
tion or experiences a second or subsequent episode of 
ENL, which lasts less than 24 weeks and occurs 84 days 
(ie, 12 weeks) or more after stopping treatment for ENL.4
Chronic ENL is defined as occurring for more than 24 
weeks during which a patient has required ENL treatment 
either continuously or where any treatment- free period is 
27 days or less.4
Recurrent ENL is defined as occurring if a patient expe-
rienced a second or subsequent episode of ENL occur-
ring between 28 and 84 days after stopping treatment for 
ENL.4
Erythema Nodosum Leprosum International STudy 
(ENLIST) ENL severity scale (EESS) is a 10- item vali-
dated severity scale which will be used as an outcome 
measurement.
Study design
MTX and prednisolone study in ENL (MaPs) is a multi-
centre double- blind RCT with two treatment arms, to 
study the efficacy of MTX and prednisolone in ENL 
compared with prednisolone and placebo. Participants 
will be stratified by type of ENL (acute or chronic/recur-
rent). The procedures for both types will be the same, 
however, they will be analysed separately.
Specialist leprosy referral institutions from six countries 
will participate in this study: DBLM Hospital Nilphamari; 
The Leprosy Mission Bangladesh; Oswaldo Cruz Insti-
tute; Rio de Janeiro, Brazil; the ALERT Center, Addis 
Ababa, Ethiopia; The Leprosy Mission Trust India, New 
Delhi, India; Bombay Leprosy Project, Mumbai, India; Dr 
Soetomo Hospital, Surabaya, Indonesia and Anandaban 
Hospital; The Leprosy Mission Nepal, Nepal.
Participants
Participants will be the patients with leprosy diagnosed 
with ENL between 18 and 60 years of age, who give 
informed consent (online supplemental appendix 1, 
page 47). Participants must have an ENLIST EESS of 9 
or more. EESS is a 10- item clinical severity scale for ENL, 
which has been developed and validated by the ENLIST 
group.32 The range of scores possible is 0–30 and a score 
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of 9 or more has been shown to be associated with more 
severe ENL. Participants must also have at least 10 cuta-
neous ENL lesions.
Patients with longstanding ENL of more than 4 years, 
pregnant and breastfeeding women, patients coinfected 
with hepatitis B or C or HIV, tuberculosis, pulmonary 
fibrosis and individuals with contra- indications to MTX 
will be excluded. Male and female patients not willing 
to practise contraception for the duration of the study 
will be excluded (in view of the teratogenic potential 
of MTX). Inclusion and exclusion criteria are listed in 
online supplemental appendix 2.
Outcomes
 ► Primary outcomes
The primary outcomes of interest are the proportion 
of individuals who have not required additional predni-
solone during the first 24 weeks and the first 48 weeks. 
These measurements were chosen because the require-
ment for additional prednisolone is an objective marker 
of ENL relapse and treatment failure.
 ► Secondary outcomes
The secondary outcomes to be assessed by comparisons 
between treatment arms are as follows. (1) The propor-
tion of individuals with adverse events (AEs), (2) the 
proportion of individuals who do not require predniso-
lone at 60 weeks, (3) the number of flares of ENL per 
individual requiring additional prednisolone up to 60 
weeks,(4) the maximal severity of flares of ENL requiring 
additional prednisolone up to 60 weeks, (5) the change 
in EESS score from baseline to the first flare of ENL 
requiring additional prednisolone, (6) the proportion 
of individuals who have not required additional pred-
nisolone in the 60 weeks of the trial. (7, 8 and 9) The 
changes in patient- reported health- related quality of life 
(HRQoL) at 24, 48 and 60 weeks.
Participants will be assessed clinically and with investi-
gations including a full blood count, renal function and 
liver function tests. Validated local language versions 
of the Dermatology Life Quality Index and the 36- item 
Short Form Survey will be used to assess HRQoL.
Randomisation and allocation concealment
Each drug pack is identified by a serial number and the 
contents determined by a process of block randomisation 
that ensures an equal number of active and placebo treat-
ments within each block.
Drug packs are to be distributed to centres in a way 
that maintains the serial numbering, so there will be only 
minor differences in the number of active and placebo 
drug packs available in each centre. In each centre, 
the drug packs are to be distributed in order by serial 
number. The key will be held by the Principal Investi-
gator (PI), study manager and local PI of each centre 
and will be broken after the data analysis is completed 
or earlier for patients with severe AEs as defined by the 
protocol.
Sample size calculation
In participants with acute ENL, if MTX reduces recur-
rence requiring additional steroid treatment by 30% (ie, 
ENL recurs in 37% rather 67% as in the published study 
by Kaur et al18) then for a 90% power with α=0.05, the 
number of participants required in each arm of this RCT 
is 57. Assuming 20% loss to follow- up, we require 142 
participants.
In participants with chronic or recurrent ENL, if the 
proportion of patients taking 50% less prednisolone by 
the end of the study is increased with MTX treatment 
by 20% (assuming that 40% of those in the MTX group 
will achieve this target and 20% taking prednisolone 
will achieve this target, that is, two times the propor-
tion in the MTX arm) then for 90% power with α=0.05, 
the number of participants required in each arm of this 
RCT is 109. Assuming 20% loss of follow- up, we would 
require 274 participants with chronic/recurrent ENL.
Follow-up
Participants will be in the study for 60 weeks and will be 
reviewed on 20 occasions. Participants who miss follow- up 
appointments will be contacted by phone.
The overview of the study is shown in figure 1.
Treatment arms
All participants in the intervention arm will receive an 
initial dose of oral MTX 10 mg, which will be increased 
to 15 mg the following week. Participants weighing less 
Figure 1 Overview of methotrexateand prednisolone study 
in erythema nodosum leprosum randomised controlled trial. 
MTX,methotrexate.
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than 60 kg will continue to receive 15 mg of MTX weekly 
thereafter. Individuals weighing more than 60 kg will have 
the weekly dose of MTX increased to 20 mg from week 8.
At week 48, the MTX will be reduced to 10 mg for 
2 weeks followed by 5 mg for 2 weeks and then stopped.
In the control arm, participants will receive an equiv-
alent number of identical dummy tablets.
All trial participants will receive prednisolone for 20 
weeks. The initial dose will be 40 mg/day, reducing to 
0. The study medications received by participants are 
detailed in table 1.
Medication
All participants will be prescribed folic acid 5 mg/day to 
minimise MTX- related adverse effects.24
Adverse event
All participants will be assessed for the occurrence of 
AEs of MTX and/or prednisolone using detailed clin-
ical assessments and laboratory parameters.33
Nausea is a common AE of MTX, which may be severe 
enough to limit therapy and may lead to loss of conceal-
ment of group allocation in the study. Up to 35% of 
patients treated with MTX may experience nausea.34 
Folate supplementation can reduce nausea and prevent 
anaemia and it is recommended for patients taking 
MTX.24 35 36 Gastrointestinal (GI) AEs associated with 
corticosteroids are common in ENL trials. In a study 
in Ethiopia of 33 participants with ENL, 57% reported 
GI AEs.20 An Indian RCT reported 43% of participants 
Table 1 Treatment schedule for MaPs in ENL.
Time from 
enrolment MTX +prednisolone group Placebo +prednisolone group
Week
Methotrexate (mg/week)
(MTX tablets will be 





0 10 40 40 4
1–7 15 40 40 6
2 15 35 35 6
3 15 35 35 6
4 15 30 30 6
5 15 30 30 6
6 15 25 25 6
7 15 25 25 6
8 15/20 20 20 6/8
9 15/20 20 20 6/8
10 15/20 20 20 6/8
11 15/20 20 20 6/8
12 15/20 15 15 6/8
13 15/20 15 15 6/8
14 15/20 15 15 6/8
15 15/20 15 15 6/8
16 15/20 10 10 6/8
17 15/20 10 10 6/8
18 15/20 5 5 6/8
19 15/20 5 5 6/8
20–47 15/20 0 0 6/8
48 10 0 0 4
49 10 0 0 4
50 5 0 0 2
51 5 0 0 2
52–59 0 0 0 0
Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly and individuals weighing 60 kg or more will receive MTX 
20 mg from week 8.
ENL, erythema nodosum leprosum; MaPs, methotrexate and prednisolone study; MTX, methotrexate.
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experienced GI AEs.18 ENL is a chronic condition, there-
fore many study trial participants have a long history of 
corticosteroid use. However, even in treatment of indi-
viduals newly diagnosed with leprosy reactions, GI AEs 
are common. In a nerve function impairment (NFI) 
prophylaxis study, almost 20% of participants who 
received prednisolone experienced GI symptoms.37
In the event of a serious AE, the allocation will be 
unmasked and an individualised treatment scheme 
initiated. In the event of a minor AE, additional medi-
cation will be prescribed according to the standard of 
care, but allocation will not be unmasked.
Indications for additional corticosteroids
The indications for additional prednisolone are defined 
in the protocol as:
1. Flare or deterioration in ENL characterised by ENL 
symptoms and/or signs resulting in an increased EESS 
score to 9 or more; an increase in EESS score of 5 or 
more; orchitis not responding to conservative man-
agement and iritis not responding to topical steroids/
mydriatics.
2. New or a deterioration in nerve function impairment 
(NFI) characterised by motor impairment or sensory 
impairment.
3. Type 1 leprosy reaction.
Any participant needing additional prednisolone will 
receive a reducing course of prednisolone as per protocol 
(see online supplemental appendix 1, page 33).
Monitoring
During the study period, the study manager will monitor 
data collection. Meetings to update the progress of the 
study and identify any issue will be scheduled according 
to each centre’s needs and if necessary further training 
can be provided to address problems arising. Regular 
online meetings will be conducted with all centres to 
discuss issues and updates.
Data safety monitoring board
A data safety monitoring board (DSMB) has been estab-
lished with independent researchers with access to 
unblinded data to review the accruing data, to monitor 
the progress of the study, to assess whether there are 
any safety issues and to advise the sponsor whether to 
continue, modify or stop the trial. The DAMOCLES 
(DAta MOnitoring Committees: Lessons, Ethics, Statis-
tics) charter was used as the model for organisation of 
the DSMB.38
Data collection
Data will be collected and managed using REDCap elec-
tronic data capture tools hosted at London School of 
Hygiene & Tropical Medicine.39 REDCap is a secure, web- 
based application designed to support data capture for 
research studies providing audit trails for tracking data 
manipulation and export procedures; automated export 
procedures for seamless data downloads to common statis-
tical packages and procedures for importing data from 
external sources. Identifiable data will not be exported to 
the database but will be kept at each centre.
Data analysis
The primary objective of the statistical analyses is to eval-
uate the efficacy and safety of MTX in the treatment of 
adult participants with acute and chronic/recurrent ENL. 
The efficacy analysis will be conducted in the intent- to- 
treat population, safety analysis will be conducted in the 
safety population. The analyses for the primary outcomes 
for both parts of the trial each require a straightforward 
comparison of percentages. In addition, we will carry 
out last observation carry- forward (LOCF) analyses. This 
will mean that all subjects who are randomised will be 
analysed. However, we are aware of the limitations of 
the LOCF approach and will also apply the likelihood- 
based method of mixed- effect model repeated measures 
(MMRM).40 We will also complete per protocol analyses. 
For secondary outcomes, LOCF and MMRM analyses will 
be applied.
Data and all appropriate documentation will be stored 
for a minimum of 5 years after the completion of the 
study, including the follow- up period.
Patient and public involvement
Individuals affected by ENL were consulted about the 
need for improved treatments and willingness to partic-
ipate in clinical studies.
Ethics and dissemination
Ethical approval was obtained from the Observational/ 
Interventions Research Ethics Committee of the London 
School of Hygiene & Tropical Medicine (15762); The 
Leprosy Mission International Bangladesh Institutional 
Research Board (in process); AHRI- ALERT Ethical 
Review Committee; Ethics Committee of the Managing 
Committee of the Bombay Leprosy Project; Health 
Research Ethics Committee Dr. Soetomo; The Leprosy 
Mission Trust India Ethics Committee; the Nepal Health 
and Research Council.
This study is registered at www. clinicaltrials. gov. Results 
will be submitted for publication in peer- reviewed jour-
nals and conclusions from the work will be presented at 
each participating centre and shared with study partici-
pants and other stakeholders. This article is based on 
the third version of the study protocol reviewed on 20 
November 2018 (online supplemental appendix 1).
DISCUSSION
MaPs is a multicentre double- blind RCT, which aims to 
assess the efficacy of oral MTX in ENL. Corticosteroids 
are the most widely used drugs for the management of 
ENL. The use of prednisolone and other corticosteroids 
leads to severe complications such as infections, peptic 
ulcer, osteoporosis, glaucoma, diabetes and hyperten-
sion. Long- term use of these medications is associated 
with morbidity and mortality. Moreover, many patients 
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suffer recurrent ENL when the dose of prednisolone is 
reduced.1 MTX has been used successfully in patients 
unresponsive to thalidomide and corticosteroids, 
making it an ideal candidate as a corticosteroid- sparing 
agent.
MaPs in ENL will be the first randomised clinical trial 
evaluating MTX as an option for ENL treatment. It will 
be the first ENL RCT to use the EESS tool to assess the 
severity and response to treatment, which will represent 
a major development in evidence- based therapeutics 
for ENL. We have developed criteria to standardise the 
prescribing of additional corticosteroids that could be 
used in other clinical trials of ENL.
MaPs in ENL will contribute to the evidence for the 
treatment of ENL and improve clinical trial method-
ology in leprosy reactions. Importantly, MaPs in ENL 
will use patients’ reported outcome measures, which 
are valuable tools to assess outcomes. MTX if efficacious 
and safe will be an affordable and accessible medication 
with the potential to improve outcomes for individuals 
with this severe complication of leprosy.
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